More about

Roswell Park Comprehensive Cancer Center

News
June 27, 2018
3 min read
Save

Survivin may be target for immunotherapies in several malignancies

Survivin may be target for immunotherapies in several malignancies

Survivin, an inhibitor of apoptosis protein, may be an attractive target for a variety of immunotherapeutic approaches for cancer, according to study results.

News
June 11, 2018
2 min watch
Save

VIDEO: Cancer vaccine targets glioblastoma

VIDEO: Cancer vaccine targets glioblastoma

CHICAGO — Michael Ciesielski, PhD, assistant professor in the department of neurosurgery at Roswell Park Comprehensive Cancer Center, spoke with HemOnc Today at ASCO Annual Meeting about SurVaxM.

News
April 23, 2018
5 min read
Save

Studies offer new insights into treatment of children, adolescents with Hodgkin lymphoma

Studies offer new insights into treatment of children, adolescents with Hodgkin lymphoma

Two Children’s Oncology Group studies suggest progress has been made in the treatment of and survival outcomes for children and adolescents with Hodgkin lymphoma.

News
April 17, 2018
3 min read
Save

Pembrolizumab plus CMP-001 demonstrates efficacy for anti-PD-1 resistant melanoma

Pembrolizumab plus CMP-001 demonstrates efficacy for anti-PD-1 resistant melanoma

The combination of pembrolizumab and CMP-001, an intratumoral toll-like receptor 9 agonist, demonstrated antitumor activity among patients with metastatic melanoma resistant to PD-1 checkpoint inhibition, according to study results presented at American Association for Cancer Research Annual Meeting.

News
April 16, 2018
5 min read
Save

Neoadjuvant nivolumab induces pathologic responses in advanced resectable non-small cell lung cancer

Neoadjuvant nivolumab induces pathologic responses in advanced resectable non-small cell lung cancer

CHICAGO — Neoadjuvant therapy with the anti-PD-1 therapy nivolumab induced responses among nearly half of patients with resectable lung cancer, according to study results presented at American Association for Cancer Research Annual Meeting.

News
April 16, 2018
6 min read
Save

Immunotherapy-chemotherapy combination extends survival in newly diagnosed metastatic lung cancer

Immunotherapy-chemotherapy combination extends survival in newly diagnosed metastatic lung cancer

CHICAGO — The addition of the anti-PD-1 therapy pembrolizumab to chemotherapy significantly improved outcomes among patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer who do not harbor EGFR or ALK alterations, according to results of the randomized phase 3 KEYNOTE-189 trial presented at American Association for Cancer Research Annual Meeting.

News
March 07, 2018
3 min read
Save

Consensus recommendations aim to align management of immunotherapy side effects

Consensus recommendations aim to align management of immunotherapy side effects

The Society for Immunotherapy of Cancer released the first set of consensus recommendations on the diagnosis and management of immune checkpoint inhibitor-related adverse events.

News
February 16, 2018
4 min read
Save

Roswell Park Comprehensive Cancer Center launches novel adoptive T-cell therapy trial

Roswell Park Comprehensive Cancer Center launches novel adoptive T-cell therapy trial

A clinical trial underway at Roswell Park Comprehensive Cancer Center is designed to assess the safety and efficacy of a two-pronged strategy that arms the immune system to more effectively attack cancer cells.

News
January 17, 2018
4 min read
Save

Multivitamins may reduce risk for chemotherapy-induced peripheral neuropathy

Multivitamins may reduce risk for chemotherapy-induced peripheral neuropathy

Multivitamin supplements may reduce incidence of chemotherapy-induced peripheral neuropathy among women undergoing treatment with paclitaxel for breast cancer, according to results of a study led by researchers at Roswell Park Comprehensive Cancer Center.

News
December 27, 2017
16 min read
Save

Toxicities associated with immunotherapy warrant ‘very high level of suspicion’

Toxicities associated with immunotherapy warrant ‘very high level of suspicion’

Since 2011, the FDA has approved six immune checkpoint inhibitors designed to reverse the course of multiple cancers.

View more